3-(dioctadecylamino)propanol | 37519-48-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(dioctadecylamino)propanol
• 英文别名: N,N-dioctadecyl-3-aminopropanol；3-(dioctadecylamino)propan-1-ol
• CAS: 37519-48-5
• 化学式: C₃₉H₈₁NO
• 分子量: 580.078
• InChiKey: RBODGFGDRNMHIX-UHFFFAOYSA-N

物化性质

• 沸点：
  644.4±28.0 °C(Predicted)
• 密度：
  0.856±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  17.6
• 重原子数：
  41
• 可旋转键数：
  37
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(dioctadecylamino)propanol 在 四溴化碳 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 以13%的产率得到1,1-dioctadecylazetidinium bromide
  参考文献：
  名称：

  功能化脂质的合成及其在可调节的核苷和核酸疏水化中的应用

  摘要：

  制备了两个功能化的单侧链和双侧链脂质分子（方案1和2）。该化合物带有末端COOH，OH或卤素取代基。此外，双侧链脂质18带有内部炔烃官能团。后一种化合物通过碱催化的烷基化作用在N（3）处使胸苷疏水化。此外，完全保护的胸苷，32，是N（3）烷基化与所述双面链醇9施加光延反应条件。

  DOI：

  10.1002/hlca.201100410
• 作为产物：
  描述：

  methyl N,N-dioctadecyl-3-aminopropanoate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以98%的产率得到3-(dioctadecylamino)propanol
  参考文献：
  名称：

  功能化脂质的合成及其在可调节的核苷和核酸疏水化中的应用

  摘要：

  制备了两个功能化的单侧链和双侧链脂质分子（方案1和2）。该化合物带有末端COOH，OH或卤素取代基。此外，双侧链脂质18带有内部炔烃官能团。后一种化合物通过碱催化的烷基化作用在N（3）处使胸苷疏水化。此外，完全保护的胸苷，32，是N（3）烷基化与所述双面链醇9施加光延反应条件。

  DOI：

  10.1002/hlca.201100410

文献信息

• REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS
  申请人：Ionovation GmbH

  公开号：US20190175633A1

  公开（公告）日：2019-06-13

  The present invention relates to a method for the isolation and/or identification of known or unknown sequences of nucleic acids (target sequences) optionally marked with reporter groups by base specific hybridation with complementary sequences using nucleolipids. The nucleolipids are prepared by lipophilizing nucleosides of formula (Ia) wherein Q represents a group having a substituted tetrahydrofuran ring and Bas represents a group having one or more heterocyclic rings having one or more heterocyclic nitrogen atoms.

  本发明涉及一种方法，用于通过碱特异性杂交与互补序列使用核苷酸脂质来分离和/或识别带有报告基团的已知或未知核酸序列（目标序列）。所述核苷酸脂质是通过使式（Ia）的核苷的亲脂化制备的， 其中，Q代表具有取代四氢呋喃环的基团，Bas代表具有一个或多个含有一个或多个杂环氮原子的杂环环的基团。
• Reactive, lipophilic nucleoside building blocks for the synthesis of hydrophobic nucleic acids
  申请人：Ionovation GmbH

  公开号：EP2712869A1

  公开（公告）日：2014-04-02

  The present invention relates to a method for the isolation and/or identification of known or unknown sequences of nucleic acids (target sequences) optionally marked with reporter groups by base specific hybridation with, essentially, complementary sequences (in the following referred to as sample oligonucleotides, sample sequences or sample nucleic acids), which belong to a library of sequences. Further, the invention relates to nucleolipids used in the method of the invention and a process for the preparation of said nucleolipids.

  本发明涉及一种用于通过与基本上互补序列（以下简称为样品寡核苷酸、样品序列或样品核酸）的碱基特异性杂交来分离和/或鉴定已知或未知核酸序列（目标序列）的方法，该目标序列可以选择性地标记有报告基团，这些目标序列属于一个序列库。此外，本发明涉及用于所述方法的核脂质以及用于制备所述核脂质的方法。
• Xylene-diamines as antiviral agents
  申请人：Pfizer Inc.

  公开号：US04034040A1

  公开（公告）日：1977-07-05

  Compounds of the formula ##STR1## or a non-toxic acid addition salt thereof wherein R.sub.1 is alkyl of from 1 to 20 carbon atoms; R.sub.2 is alkyl of from 12 to 20 carbon atoms; R.sub.3 is selected from the group consisting of hydrogen and hydroxyalkyl of from 2 to 8 carbon atoms; and R.sub.4 is selected from the group consisting of hydrogen, alkyl of from 1 to 8 carbon atoms and hydroxyalkyl of from 2 to 8 carbon atoms, said compounds are useful for combating viral infections in vertebrate animals.

  式##STR1##的化合物或其非毒性酸盐，其中R.sub.1是由1至20个碳原子组成的烷基；R.sub.2是由12至20个碳原子组成的烷基；R.sub.3选自由2至8个碳原子的氢和羟基烷基组成的群；R.sub.4选自由1至8个碳原子的氢、烷基和由2至8个碳原子组成的羟基烷基，这些化合物对于对抗脊椎动物的病毒感染是有用的。
• Interferon induction in animals by amines
  申请人：Pfizer Inc.

  公开号：US04087552A1

  公开（公告）日：1978-05-02

  Combating viral infections in vertebrate animals by administering to the animals an amine selected from those having the formulae: ##STR1## and the non-toxic acid addition salts thereof wherein R.sub.1 is selected from the group consisting of alkyl of from 1 to 20 carbon atoms, aralkyl, aryloxyalkyl, hydroxyalkyl of from 2 to 8 carbon atoms and ##STR2## R.sub.2 is selected from the group consisting of alkyl of from 12 to 20 carbon atoms, aralkyl and aryloxyalkyl of from 12 to 24 carbon atoms and ##STR3## R.sup.o is alkoxy of from 1 to 18 carbon atoms; EACH OF R' and R" is selected from the group consisting of hydrogen, alkyl, alkoxy of from 1 to 18 carbon atoms; R' and R" when taken together are methylenedioxy; Provided that the total number of carbon atoms in R.sup.o, R' and R" is from 5 to 48; R.sub.3 is selected from the group consisting of hydrogen, alkyl of from 1 to 20 carbon atoms, hydroxyalkyl of from 2 to 8 carbon atoms, phenylcarbamoyloxy(lower alkyl), .omega.-carboxyalkanoyloxy(lower alkyl), allyl, alkanoyl of from 1 to 6 carbon atoms, alkanoyloxy(lower alkyl), carbo(lower alkoxy)lower alkyl, carboxy(lower alkyl), alkoxy(lower alkyl) and gem-di(lower alkoxy)lower alkyl; R.sub.4 is selected from the group consisting of hydrogen, alkyl of from 1 to 8 carbon atoms, hydroxyalkyl of from 2 to 8 carbon atoms, carbo(lower alkoxy)lower alkyl, alkanoyloxy(lower alkyl), carboxy(lower alkyl), alkoxy(lower alkyl), phenyl-carbamoyloxy(lower alkyl), .omega.-carboxyalkanoyloxy(lower alkyl), allyl, dihydroxyalkyl of from 3 to 8 carbon atoms, and morpholinoethyl; with the proviso that no more than two of the R variables are hydroxyalkyl; R.sub.3 and R.sub.4 when taken together with the nitrogen to which they are attached are morpholino; X is selected from the group consisting of straight chain alkylene of from 2 to 6 carbon atoms and ##STR4## X' is selected from the group consisting of X, phenylenedimethylene and ##STR5## m is 0 or 1, with the provisos that only one of X and X'is ##STR6## and when X' is phenylenedimethylene, m is 0; Y is selected from the group consisting of straight chain alkylene of from 2 to 8 carbon atoms and phenylenedimethylene; A is selected from the group consisting of hydrogen, cyano, hydroxy, alkoxy of from 1 to 20 carbon atoms, alkanoyloxy of from 2 to 20 carbon atoms, phenylcarbamoyloxy, chloro, bromo, .omega.-carboxyalkanoyloxy(lower alkyl), alkanoyloxy of from 1 to 6 carbon atoms, carbo(lower alkoxy) and alkanoylthio of from 2 to 20 carbon atoms and alkylthio of from 1 to 20 carbon atoms; R.sub.5 is selected from the group consisting of hydrogen, alkyl of from 1 to 20 carbon atoms, hydroxyalkyl of from 2 to 8 carbon atoms, (lower alkoxy)lower alkyl and ##STR7## R.sub.6 is selected from the group consisting of hydrogen, alkyl of from 12 to 20 carbon atoms, hydroxyalkyl of from 2 to 8 carbon atoms, (lower alkoxy)lower alkyl and ##STR8## R.sub.7 is selected from the group consisting of alkyl of from 12 to 20 carbon atoms and ##STR9## R.sub.8 is selected from the group consisting of alkyl of from 1 to 20 carbon atoms and ##STR10## each of p and n is 0 or an integer from 1 to 6, with the proviso that the sum of p and n is no greater than 6; and Z is selected from the group consisting of .omega.-carboxy(lower alkyl), morpholino, piperidino, piperazino, N-(.omega.-hydroxy lower alkyl)piperazino and N-(lower alkyl)piperazino.

  通过向脊椎动物内部注射选择自以下具有以下式的胺类化合物或其无毒酸加成盐的方法来对抗脊椎动物中的病毒感染：其中R1选自由1至20个碳原子的烷基，芳基烷基，芳氧基烷基，由2至8个碳原子的羟基烷基和-（CH2）n-（CH2）p-的组成; R2选自由12至20个碳原子的烷基，芳基烷基和芳氧基烷基组成; R0是由1至18个碳原子的烷氧基组成; 每个R'和R"选自氢，烷基，由1至18个碳原子的烷氧基;当R'和R"一起取时，它们是亚甲二氧基; 前提是R0，R'和R"中碳原子的总数为5至48; R3选自氢，由1至20个碳原子的烷基，由2至8个碳原子的羟基烷基，苯基氨基羧酸酯（低烷基），ω-羧基烷酰氧（低烷基），烯丙基，由1至6个碳原子的烷酰基，烷酰氧（低烷基），羧基（低烷基），烷氧（低烷基）和双（低烷氧基）烷基; R4选自氢，由1至8个碳原子的烷基，由2至8个碳原子的羟基烷基，羧基（低烷基），烷酰氧（低烷基），羧基（低烷基），烷氧（低烷基），苯基氨基羧酸酯（低烷基），ω-羧基烷酰氧（低烷基），烯丙基，由3至8个碳原子的二羟基烷基和吗啉基乙基; 前提是R变量中最多只有两个是羟基烷基; 当R3和R4与它们连接的氮一起取时，它们是吗啉; X选自由2至6个碳原子的直链烷基和-（CH2）n-的组成; X'选自X，苯二甲亚基和-（CH2）n-的组成; m为0或1，前提是X和X'中只有一个是-（CH2）n-，当X'是苯二甲亚基时，m为0; Y选自由2至8个碳原子的直链烷基和苯二甲亚基组成; A选自氢，氰基，羟基，由1至20个碳原子的烷氧基，由2至20个碳原子的烷酰氧基，苯基氨基羧酸酯，氯，溴，ω-羧基烷酰氧（低烷基），由1至6个碳原子的烷酰氧基，羧基（低烷氧基），由2至20个碳原子的烷酰硫基和由1至20个碳原子的烷硫基; R5选自氢，由1至20个碳原子的烷基，由2至8个碳原子的羟基烷基，（低烷氧基）烷基和-（CH2）n-的组成; R6选自氢，由12至20个碳原子的烷基，由2至8个碳原子的羟基烷基，（低烷氧基）烷基和-（CH2）n-的组成; R7选自由12至20个碳原子的烷基和-（CH2）n-的组成; R8选自由1至20个碳原子的烷基和-（CH2）n-的组成; p和n中的每一个都是0或1至6的整数，前提是p和n的总和不大于6; Z选自ω-羧基（低烷基），吗啉基，哌啶基，N-（ω-羟基低烷基）哌嗪和N-（低烷基）哌嗪的组成。
• 5-Fluorouracil Derivatives
  申请人：B. Braun Melsungen AG

  公开号：US20150291649A1

  公开（公告）日：2015-10-15

  The present invention relates to 5-fluorouracil derivatives represented by formula (i), pharmaceutical compositions comprising said derivative and their use in the treatment of cancer as well as a process for preparing the 5-fluorouracil derivative represented by formula (I).

  本发明涉及由式（i）表示的5-氟尿嘧啶衍生物，包括该衍生物的制药组合物及其在癌症治疗中的应用，以及制备由式（I）表示的5-氟尿嘧啶衍生物的过程。